Clinical Trial Update: Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed proteasome inhibition to reduce anti-donor HLA antibody production after kidney transplantation; results were posted though the study w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Mark Stegall | Conditions: Disorder of Transplanted Kidney | Phase 2 | Status: TERMINATED | Results posted: 2015-09-09